Research brief
Revolution Medicines closed at $186.9 on 10 July, down 1.2% for the week but still up 21.5% over four weeks and 25.7% over 12 weeks. The biotechnology stock sits 3.6% below its 52-week high, 51.1% above its weekly Trend Line and 235.1% above Sharemaestro Fair Value, leaving the setup constructive but stretched. The main caveat is confirmation: latest volume was 9.2M shares, only 0.5x the 13-week average, while the activity-pressure state stayed positive without a fresh confirmation signal.
- Latest close: $186.9, down 1.2% on the week but 21.5% higher over four weeks.
- The weekly Trend Signal remains active, with 44 active weeks and 84.6% trend breadth for RVMD’s own 52-week window.
- Price is 51.1% above the $123.7 Trend Line and only 3.6% below the $193.8 52-week high.
- Volume was light at 9.2M shares, versus a 13-week average of 16.9M and a 52-week average of 13.2M.
- US Biotechnology breadth is supportive, with 58.0% trend breadth, 73.0% positive Market Dynamics and 67.0% positive Relative Strength, but RVMD lagged the industry’s 0.7% weekly gain.
A constructive biotechnology chart, but the chase has cooled
Revolution Medicines, a $33.5B precision oncology developer focused on RAS-addicted cancers, ended the week at $186.9 after slipping 1.2%. That pause is small in the context of the prior advance: the stock is still up 21.5% over four weeks, 25.7% over 12 weeks, 57.5% over 26 weeks and 391.5% across the past year. The close sits at 95.7% of the 52-week range, leaving RVMD just 3.6% below its $193.8 high and far above the $34.00 low.
Trend state stays positive while valuation distance widens
The Sharemaestro Trend Signal remains active, supported by a 44-week active streak and a close 51.1% above the $123.7 weekly Trend Line. Market Dynamics are also positive, with activity pressure at 1.27, while Relative Strength remains elevated at 77.39. The balanced setup comes from the other side of the ledger: the stock trades 235.1% above Sharemaestro Fair Value of $55.78, and activity pressure did not register a fresh confirmation signal despite the constructive regime.
Sector context favours biotech, though RVMD’s weekly rank softened
Healthcare was weak on the week, with the sector group down 1.8% on average and only 36.0% positive Relative Strength breadth. RVMD’s 1.2% decline was better than the broad Healthcare average, but it ranked near the middle of the wider US Healthcare cohort. The more relevant industry picture is stronger: US Biotechnology gained 0.7% on average for the week, with 58.0% trend breadth, 73.0% positive Market Dynamics and 67.0% positive Relative Strength.
Volume is the weak spot in the current evidence
The latest week traded 9.2M shares, well below the 16.9M 13-week average and the 13.2M one-year average. That contrasts with the 24.9M-share week on 26 June, when RVMD gained 11.7%, and the 45.3M-share burst in April that coincided with a 54.1% weekly gain. The current price level is strong, but the latest move lacks the same participation evidence that marked earlier advances.
Risk is now about exhaustion as much as direction
Recent volatility remains high, with 13-week weekly-return volatility at 14.7% versus a 52-week base of 11.2%. The up/down profile is still favourable, with 35 positive weeks against 17 negative weeks over the past year and an average positive week of 7.3% versus an average negative week of 4.0%. Even so, five recent reversal markers, a large fair-value premium and a close near the top of the annual range make follow-through quality more important than the direction of a single week.
What to watch next
The immediate test is whether RVMD can hold its range-top position while activity pressure remains positive and volume improves. The $123.7 Trend Line is the key weekly regime level if the pullback deepens, while a volume ratio above 1.5x would provide stronger evidence that institutions are participating in the next directional move. Without that, the stock can remain technically strong but vulnerable to a sharper reset if momentum loses urgency.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/rvmd-near-high-volume-gap-four-week-run/.
Media and research systems can follow the RSS feed or JSON feed.